Evidence map›Paper›PMID 27356749›Full record

ArticleOncotarget2016

Baicalein is an available anti-atherosclerotic compound through modulation of nitric oxide-related mechanism under oxLDL exposure.

Shih-Hung Chan, Ching-Hsia Hung, Jhih-Yuan Shih, Pei-Ming Chu, Yung-Hsin Cheng, Yi-Ju Tsai, Huei-Chen Lin, Kun-Ling Tsai

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Shih-Hung ChanDepartment of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Ching-Hsia HungInstitute of Allied Health Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Jhih-Yuan ShihDepartment of Internal Medicine, Chi-Mei Hospital, Tainan, Taiwan.
Pei-Ming ChuDepartment of Anatomy, School of Medicine, China Medical University, Taichung, Taiwan.
Yung-Hsin ChengDepartment of Education and Research, Taipei City Hospital, Taipei, Taiwan.
Yi-Ju TsaiDepartment of Physical Therapy, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Huei-Chen LinInstitute of Allied Health Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Kun-Ling TsaiDepartment of Physical Therapy, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
National Cheng Kung University · TWChi Mei Medical Center · TWChina Medical University · TWNational Cheng Kung University Hospital · TWTaipei City Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

OxLDL facilitate reactive oxygen species (ROS) formation and up-regulation of the executioner caspase-3 via the mitochondrial apoptotic pathway involves several critical steps in human endothelial cells. Previous studies reported that oxLDL-facilitated endothelial oxidative stress is associated with impairment of eNOS and up-regulation of inducible nitric oxide synthase (iNOS). Baicalein is the most abundant component that has anti-HIV, anti-tumor, anti-oxidant and free radical scavenging functions. In this present study, we shown that baicalein hinibits oxLDL-caused endothelial dysfunction through suppression of endothelial inflammation and oxidative stress that causes to cellular apoptosis. Specifically, baicalein reduces the elevation of ROS concentration, which subsequently inhibits the oxLDL-decreased expression of anti-oxidant enzymes, enriches the bioavailability of NO, stabilizes the mitochondrial membrane, thereby inhibiting the discharge of cytochrome c from mitochondria, a molecule required for the activation of the pro-apoptotic protein caspase 3. However, inhibition of eNOS impairs the anti-apoptotic and anti-inflammatory effects of baicalein. These results provide new insight into the possible molecular mechanisms by which baicalein protects against atherogenesis by NO-related pathways.

Indexed as

ApoptosisAtherosclerosisCaspase 3Cells, CulturedEnzyme ActivationFlavanonesHumansHuman Umbilical Vein Endothelial CellsLipoproteins, LDLNitric OxideNitric Oxide Synthase Type IINitric Oxide Synthase Type IIIOxidative StressReactive Oxygen SpeciesSignal TransductionbaicaleinCaspase 3FlavanonesLipoproteins, LDLNitric OxideNitric Oxide Synthase Type IINitric Oxide Synthase Type IIIoxidized low density lipoproteinReactive Oxygen Speciesbaicaleinendothelial cellsGerotargetnitric oxideoxidized low-density lipoproteinreactive oxygen species

Identifiers

PMID27356749
PMCPMC5189994
OpenAlexW2464860672

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.